Legal & General Group Plc acquired a new position in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY – Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 306,265 shares of the medical instruments supplier’s stock, valued at approximately $3,249,000.
Other large investors have also recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of DENTSPLY SIRONA during the first quarter valued at $26,000. Eurizon Capital SGR S.p.A. purchased a new stake in DENTSPLY SIRONA during the fourth quarter valued at about $26,000. Caitong International Asset Management Co. Ltd raised its holdings in shares of DENTSPLY SIRONA by 337.9% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier’s stock worth $35,000 after purchasing an additional 2,122 shares during the period. Farther Finance Advisors LLC lifted its stake in shares of DENTSPLY SIRONA by 119.1% in the 4th quarter. Farther Finance Advisors LLC now owns 3,773 shares of the medical instruments supplier’s stock valued at $43,000 after purchasing an additional 2,051 shares in the last quarter. Finally, Performa Ltd US LLC grew its holdings in shares of DENTSPLY SIRONA by 116.1% during the 4th quarter. Performa Ltd US LLC now owns 4,250 shares of the medical instruments supplier’s stock worth $49,000 after purchasing an additional 2,283 shares during the period. Institutional investors and hedge funds own 95.70% of the company’s stock.
DENTSPLY SIRONA Trading Down 0.4%
Shares of NASDAQ XRAY opened at $11.38 on Friday. The stock has a market capitalization of $2.27 billion, a P/E ratio of -4.14, a PEG ratio of 1.45 and a beta of 0.84. The stock’s 50 day moving average price is $12.16 and its two-hundred day moving average price is $11.67. The company has a quick ratio of 1.07, a current ratio of 1.63 and a debt-to-equity ratio of 1.48. DENTSPLY SIRONA Inc. has a 52-week low of $9.40 and a 52-week high of $14.86.
Analysts Set New Price Targets
A number of analysts recently issued reports on the stock. Barrington Research set a $15.00 target price on shares of DENTSPLY SIRONA in a research report on Monday, August 10th. Barclays boosted their price target on DENTSPLY SIRONA from $9.00 to $11.00 and gave the stock an “underweight” rating in a research report on Monday, August 24th. BMO Capital Markets restated a “market perform” rating and issued a $13.00 price target on shares of DENTSPLY SIRONA in a report on Friday, August 7th. Weiss Ratings reissued a “sell (e+)” rating on shares of DENTSPLY SIRONA in a research report on Monday, August 3rd. Finally, Piper Sandler upped their target price on shares of DENTSPLY SIRONA from $13.00 to $14.00 and gave the company a “neutral” rating in a research note on Wednesday, July 29th. Three investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $13.54.
Read Our Latest Report on DENTSPLY SIRONA
Insider Buying and Selling
In other DENTSPLY SIRONA news, Director Brian Gladden bought 9,985 shares of the business’s stock in a transaction on Monday, June 15th. The shares were purchased at an average price of $10.02 per share, with a total value of $100,049.70. Following the completion of the acquisition, the director directly owned 61,849 shares of the company’s stock, valued at approximately $619,726.98. The trade was a 19.25% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Michael Barber bought 15,175 shares of the firm’s stock in a transaction on Thursday, June 11th. The stock was bought at an average price of $9.88 per share, with a total value of $149,929.00. Following the completion of the purchase, the director owned 55,943 shares of the company’s stock, valued at $552,716.84. This trade represents a 37.22% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 35,160 shares of company stock worth $351,179 over the last quarter. 0.46% of the stock is owned by company insiders.
About DENTSPLY SIRONA
Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.
The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.
Featured Articles
- Five stocks we like better than DENTSPLY SIRONA
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Want to see what other hedge funds are holding XRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DENTSPLY SIRONA Inc. (NASDAQ:XRAY – Free Report).
Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.
